Pivotal Point Tracking Moderna (MRNA): US Biotech Pioneer Records a 177% Surge After Phase-3 Study Successes on the Stock Market
Reading Time: 1 minute
Moderna is a US biotech company specializing in messenger RNA (mRNA) drugs. On August 19, the company published positive phase-3 results for the cancer drug Intismeran against skin cancer in collaboration with Merck. In combination with Keytruda, the personalized therapy significantly reduced the risk of relapse compared to monotherapy – the first successful late-stage study of its kind. Moderna benefits in two ways from mRNA technology. First, the expansion beyond infectious diseases allows entry into the lucrative oncology market, where clinical...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
